"Selayang Hospital is a fully government hospital with 960 inpatient beds and 20 clinical disciplines located in Selayang in the Gombak District, Selangor, Malaysia. This hospital provides secondary and selected national tertiary care services. Located in Batu Caves, Malaysia."

During the past decade, Hospital Selayang conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 10 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 7 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Selayang" #1 sponsor was "Janssen Research & Development, LLC" with 7 trials, followed by "Pfizer" with 2 trials sponsored, "Selayang Hospital" with 2 trials sponsored, "Ark Biosciences Inc." with 1 trials sponsored and "BBraun Medical SAS" with 1 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Selayang" #1 collaborator was "Ark Biosciences Pty Ltd." with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "Hexal AG" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Selayang" are "Arthritis, Psoriatic" (5 trials), "Rheumatoid Arthritis" (2 trials), "Acute Kidney Injury" (1 trials), "Acute Renal Failure" (1 trials) and "Adnexal Mass" (1 trials). Many other conditions were trialed in "Hospital Selayang" in a lesser frequency.

Most popular intervention types in "Hospital Selayang" are "Drug" (18 trials), "Other" (3 trials), "Biological" (2 trials), "Device" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Guselkumab" (5 trials), "AK0529" (1 trials), "Adalimumab - GP2017" (1 trials) and "Adalimumab - US licensed Humira" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Selayang" are 27 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Selayang". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Hospital Selayang, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Selayang, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 5 trials that are defined as “Not Applicable".